CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
SeraCare Life Sciences’ new precision medicine business unit has launched its first product, the Seraseq Solid Tumor Mutation Mix—I (AF20), a biosynthetic reference material designed to evaluate the performance of next-generation-sequencing–based tumor profiling assays. This product contains a mixture of mutations in key oncogenes and tumor suppressor genes and is intended as a quality material for translational and disease research testing. It also permits laboratories to monitor library preparation, sequencing, and variant allele detection under a given set of bioinformatics pipelines or parameters.
This first version includes 26 major cancer hot-spot genes, all at 20 percent allelic frequency and quantitated using digital PCR to ensure accuracy. It is stable for two years under recommended storage conditions and can undergo 10 freeze-thaw cycles without any degradation of performance. It is currently for research use only.
SeraCare Life Sciences, 508-244-6400